Related Experiment Video
Updated: Jan 24, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Integrated Network Pharmacology, LC-MS/MS, and Experimental Validation of Fangji-astragalus in Hyperlipidemia
Wangqin Wu1, Mi Zhang1, Chunlei Fan1
1School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Introduction:
Hyperlipidemia is linked to multiple cardiovascular and cerebrovascular diseases. Traditional Chinese Medicine formulations show potential for managing this condition, but the underlying mechanisms remain unclear. This study investigates the therapeutic effects of the Fangji-Astragalus (FJ-HQ) on hyperlipidemia and explores its key components and molecular pathways.
Methods:
Network pharmacology was applied to identify active ingredients in FJ-HQ and drugdisease co-targets. Transcriptomic analysis and HPLC-MS/MS were integrated to screen core components and associated targets. In vivo and in vitro experiments evaluated the effects of FJHQ in hyperlipidemic rat models and cell models.
Results:
A total of 23 active ingredients and 109 drug.disease co-targets were identified, with enrichment in inflammatory and signaling pathways, notably the PI3K/AKT/mTOR and p53 pathways. Transcriptomic profiling revealed seven differentially expressed targets. Integrated chemical and serum analysis identified calycosin as the core component and highlighted CAMTA2 and RXRA as downstream targets. In hyperlipidemic rats, FJ-HQ lowered total cholesterol, triglycerides, and low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol and apolipoprotein A1. FJ-HQ also modulated the expression of P53, AKT1, and IL6, as well as mRNA levels within the PI3K/AKT/mTOR pathway. In cell models, serum containing FJ-HQ inhibited lipid droplet formation.
Discussion:
These findings demonstrate that FJ-HQ alleviates hyperlipidemia by modulating the PI3K/AKT/mTOR and p53 pathways, reducing lipid levels, and suppressing lipid droplet formation, with calycosin as a pivotal active component.
Conclusion:
In summary, our study confirms the therapeutic effects of FJ-HQ on hyperlipidemia and identifies calycosin as a crucial component. Furthermore, we have experimentally validated the influence of FJ-HQ on the PI3K/AKT/mTOR signaling pathway. These findings highlight the potential of FJ-HQ as an effective lipid-lowering agent and provide preclinical evidence for future treatments of hyperlipidemia.
More Related Videos
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
10:15Integration of 5G Experimentation Infrastructures into a Multi-Site NFV Ecosystem
Published on: February 3, 2021
Related Concept Videos
Reliability and Validity
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Protein Networks
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Data Validation
Key parameters for method validation include: